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Introduction
The development of vectors for target-cell specific gene delivery is a major goal of gene therapeutic strategies. Thereby nonviral gene delivery vectors are gaining increasing interest.
1,2 While they are still relatively inefficient, they might present a suitable alternative to viral vectors since they overcome major disadvantages of viruses such as the lack of cell type specificity with regard to their infectivity, the restriction in the size of incorporated DNA, and safety considerations due to the presence of viral genomic sequences. Progress has been made in the understanding of how individual activities of viruses can be mimicked and methodologies have been developed which allow the combination of different functions required for gene transfer into an artificial complex.
Molecular conjugates which employ antibodies or other ligands chemically coupled to polycations to deliver DNA into cells via receptor-mediated endocytosis constitute an important group of such target-cell specific, nonviral vectors. 3, 4 Another attractive approach for the design of modular self-assembling systems for gene delivery is based on fusion proteins engineered to incorporate several co-operating functions in a single polypeptide chain. [5] [6] [7] Each of these domains can account for a distinct activity required for DNA-binding, cell recognition and intracellular delivery. Such fusion proteins in contrast to chemical conjugates can be produced in suitable expression systems in their final form and the resulting products are generally homogeneous in their composition. We have recently described such a chimeric multidomain fusion protein which facilitates target-cell specific gene delivery and is based on the molecular organization of the bacterial Pseudomonas exotoxin A (ETA). 6 The 66 kDa exotoxin A consists of three functional domains defined by crystal structure and deletion analysis. 8, 9 Upon cell binding via the N-terminal cell recognition domain (Ia) and receptor-mediated internalization, ETA is cleaved by a cellular protease within the internal domain II (translocation domain) resulting in an N-terminal 28 kDa and a C-terminal 37 kDa fragment. After reduction of a disulfide bond, the C-terminal fragment containing the enzymatic domain III translocates to the cytoplasm where it ADP-ribosylates and inactivates eukaryotic elongation factor 2. 10 In the 5EG fusion protein, 6 the natural cell binding domain of ETA was replaced by a tumor-specific single chain antibody domain. Likewise, the C-terminal enzymatic domain of the toxin was exchanged with the DNA-binding domain of the yeast GAL4 transcription factor for the interaction with plasmid DNA. The internal translocation domain of ETA was retained as an endosome escape function. The resulting chimeric molecule was non-toxic, exhibited an altered target-cell tropism, and functioned as a cellspecific DNA carrier.
Due to this modular organization, similar carrier proteins with modified activities, eg different target cell specificity, might be obtained by replacing individual protein domains. This could assist in the development of gene transfer strategies optimized for distinct target cell populations. In order to explore the flexibility of this concept, we have constructed and characterized a multidomain fusion protein which employs the natural EGF receptor ligand transforming growth factor (TGF)-␣ as a cell targeting domain. EGF receptor overexpression has been observed in a high percentage of human carcinomas including glioblastoma, cancer of the lung, breast, head and neck and bladder, and correlates with an unfavorable prognosis for the patients. 11 Therefore the EGF receptor constitutes an attractive target for directed tumor therapy which includes gene therapeutic strategies. [12] [13] [14] We have fused a human TGF-␣ cDNA fragment to sequences encoding the ETA translocation domain and the GAL4 DNA-binding domain. Upon bacterial expression and purification, the resulting chimeric protein termed TEG displayed specific binding to EGF receptor expressing cells. Complexes of the fusion protein with plasmid DNA carrying a luciferase reporter gene and a GAL4 specific recognition sequence, after condensation with poly-l-lysine were able to transfect EGF receptor expressing cells in vitro. Thereby transfection efficiency and dependence on the endosomolytic reagent chloroquine varied in different cell lines demonstrating the importance of cell type-specific characteristics for successful gene delivery.
Results
Construction and bacterial expression of the TEG DNA carrier protein DNA fragments encoding amino acids 1 to 50 of human TGF-␣, domain II (translocation domain) of Pseudomonas exotoxin A, and the DNA binding domain of the yeast transcriptional activator GAL4 were derived from previously described plasmids by restriction enzyme digestion and assembled into a single open reading frame in the bacterial expression vector pFLAG-1. The resulting plasmid pWF47-TEG encodes under the control of the IPTG inducible tac promoter the chimeric fusion protein termed TEG which is schematically shown in Figure 1a . It consists of an N-terminal E. coli ompA signal peptide, a synthetic FLAG epitope, human TGF-␣, a cluster of six histidine residues facilitating the purification of the recombinant protein via Ni 2+ affinity chromatography, amino acids 252 to 366 of Pseudomonas exotoxin A, and amino acids 2 to 147 of the yeast GAL4 protein. At the C-terminus, the fusion protein carries a KDEL signal which is functionally equivalent to the C-terminal sequence of exotoxin A required for intracellular routing and full activity of the wild-type toxin. 15 The fusion protein was expressed in E. coli strain CC118 and purified under denaturing conditions from bacterial lysates via binding to Ni 2+ -saturated chelating sepharose and elution with 250 mm imidazole. Fractions containing the recombinant fusion protein were pooled, imidazole and denaturant were removed by dialysis and the protein was concentrated by ultrafiltration. SDS-PAGE analysis of the 38 kDa TEG fusion protein revealed a purity of approximately 90% after a single round of purification (Figure 1b) . Binding properties of the TEG fusion protein To investigate the functionality of the TGF-␣ domain, the binding of purified TEG protein to the recombinant EGF receptor was analyzed by ELISA. Purified TEG at concentrations ranging from 0.05 to 333 nm was added to the wells of 96-well plates coated with recombinant extracellular domain of the EGF receptor, the plates were incubated at room temperature for 1 h and specifically bound protein was determined. The results are shown in Figure  2a . TEG bound to the extracellular portion of the EGF receptor in a saturable fashion. This interaction with the EGF receptor was dependent on the TGF-␣ domain of TEG since the presence of a nine-to 40-fold molar excess of TGF␣-ETA, a recombinant toxin containing TGF-␣, 16 inhibited TEG binding almost completely (Figure 2b ). The interaction of TEG with EGF receptor was further confirmed by FACS analysis. A431 human epidermoid carcinoma cells which highly overexpress EGF receptor were incubated with TEG, and specifically bound fusion protein was detected with MAb M2 recognizing a synthetic FLAG epitope included in the recombinant protein and FITC-labeled goat anti-mouse IgG. The results are shown in Figure 2c . Significant binding of TEG protein to A431 cells was detected.
Upon cell binding, internalization of the ligand-recep- tor complex is required for the DNA-carrier protein to be effective in gene delivery. Binding of growth factors like EGF and TGF-␣ to the EGF receptor triggers receptor dimerization and autophosphorylation of specific tyrosine residues within the receptor's intracellular domain. This initiates the signal transduction cascade and also results in the recruitment of the EGF receptor to clathrincoated pits which is followed by internalization of the ligand-receptor complex along the endocytic pathway. 17 To determine whether binding of TEG to the EGF receptor induces a response similar to that initiated by natural ligands, the ability of TEG to activate EGF receptor was tested. COS-1 and A431 cells were treated for 10 min at 37°C with the fusion protein in the presence or absence of the antagonistic EGF-receptor specific MAb 14E1 16 as a competitor. Control cells were treated with PBS, MAb 14E1 alone, or 100 ng/ml EGF. Equal amounts of cell lysates were assayed for their phosphotyrosine content by SDS-PAGE and subsequent immunoblotting with a specific anti-phosphotyrosine antibody. The results are shown in Figure 3 . Treatment of cells with EGF (lanes 2 and 6) or TEG (lanes 3 and 7) led to a strong increase in the phosphotyrosine content of a protein corresponding in size with the 170 kDa EGF receptor, which was confirmed by reprobing the filter with an anti-EGF receptor serum ( Figure 3 , lower panel). This TEG-mediated activation of the receptor was specific since it was blocked by the addition of the EGF receptor specific MAb 14E1 (lanes 4 and 8). PBS and the competing antibody alone had no effect on the activation status of the receptor (lanes 1, 5 and 9). These results show that TEG like the natural EGF receptor ligand initiates receptor activation which is required for enhanced internalization of the ligand-receptor complex.
The TEG carrier protein facilitates gene transfer TEG carrier protein-mediated gene transfer was analyzed using the plasmid pSV2G4LUC, 6 which encodes a luciferase reporter gene under the control of the SV40 early promoter. The plasmid contains two consecutive GAL4-
Figure 3 Activation of the EGF receptor by the TEG fusion protein. COS-1 (lanes 1-4) and A431 cells (lanes 5-9) were grown in low serum for 8 h and then treated with 3 g/ml TEG in the absence (lanes 3 and 7) or the presence (lanes 4 and 8) of the antagonistic MAb 14E1. Control cells were treated with PBS (lanes 1 and 5), 100 ng/ml EGF (lanes 2 and 6) or 14E1 antibody (lane 9). Equal amounts of cell lysates were analyzed by SDS-PAGE and immunoblotting with an anti-phosphotyrosine MAb, followed by incubation with an anti-mouse horseradish peroxidase labeled antibody and chemiluminescent detection (upper panel). The amount of EGF receptor loaded in each lane was analyzed by reincubation of the filter with 12E EGF receptor specific antiserum (lower panel). The position of the 170 kDa EGF receptor is indicated (EGFR). M, molecular weight standards.
specific recognition sequences in the 3Ј-untranslated region of the expression cassette which allows specific binding of fusion proteins containing the GAL4 DNAbinding domain. TEG fusion protein and circular pSV2G4LUC plasmid-DNA were mixed and incubated for 15 min at room temperature to allow the formation of protein-DNA complexes. Subsequently an electroneutral complex was achieved by adding to the preincubated mixture a 50-fold molar excess of poly-l-lysine pL 236 with respect to the DNA concentration. 6 Transfection mediated by the TEG-DNA-poly-l-lysine complex (TEG-polyplex 18 ) was analyzed using COS-1 SV40-transformed monkey kidney cells in standard growth medium. These cells express approximately 1-2 × 10 5 EGF receptors per cell (W Wels, unpublished data) which are activated upon binding of TEG as shown in Figure 3 . COS-1 cells were incubated with TEGpSV2G4LUC polyplex for different time intervals, the growth medium was replaced, and the activity of the reporter gene was analyzed 48 h after initial sample addition. Cells incubated with a similar polyplex lacking the TEG fusion protein served as a control. As shown in Figure 4 , significant luciferase activity could already be detected in cells treated with TEG-polyplex for 1 h. Thereafter the expression of the reporter gene increased with incubation time in a saturable manner indicating that effective delivery of the plasmid-DNA was achieved.
In different experiments, we observed a relatively high variation in the efficiency of gene transfer ranging from 5 × 10 6 to 1 × 10 8 relative luciferase units per milligram protein when different batches of TEG carrier protein were used. Thereby, in contrast to the previously described ErbB2-specific carrier protein 5EG 6 usually relatively high concentrations of TEG (50-160 nm final concentration) were required for successful transfection. This suggests that similar to previously described recombinant toxins containing TGF-␣ 19 a major part of the purified carrier protein was inactive. Therefore an additional unfolding/refolding step was included in the purification protocol which increased the yield of functionally active TEG fusion protein and resulted in consistently high levels of reporter gene expression using lower concentrations (0.8-4 nm final concentration) of carrier protein. 
cells per well and grown overnight. Transfection complexes containing the TEG fusion protein, pSV2G4LUC luciferase reporter plasmid and poly-l-lysine (TEG-pSV2G4LUC polyplex) were prepared as described in Materials and methods and added to the cells in normal growth medium. The cells were incubated with TEG-pSV2G4LUC polyplex (TEG) at a final concentration of partially refolded TEG of 160 nm for 10 s, or 0.5, 1, 2, 4 or 21 h as indicated. Control cells were treated with pSV2G4LUC polyplex lacking the fusion protein (pL). Cells were harvested and reporter gene expression was analyzed 48 h after the addition of polyplex. Luciferase activity is expressed in relative light units per milligram of total protein.
TEG-mediated gene transfer is dependent on specific binding to DNA and to the EGF receptor Complexes of TEG and pSV2G4LUC plasmid-DNA were prepared as described above and, after condensation with poly-l-lysine were added to COS-1 cells in normal growth medium for 16 h. The medium was replaced and luciferase activity was analyzed 36 h later. As shown in Figure 5a , under these conditions cells treated with TEGpolyplex displayed up to 150-fold higher reporter gene activity than control cells treated with polyplex lacking the carrier protein. To investigate the dependence of TEG-mediated gene transfer on the specific interaction of the GAL4 DNA-binding domain with its cognate DNA recognition sequence, COS-1 cells were treated with polyplex containing TEG and either pSV2G4LUC or the similar pSV2LUC plasmid which lacks GAL4-specific DNA recognition sequences. As shown in Figure 5b in the absence of a GAL4-specific recognition sequence the efficiency of TEG-mediated gene transfer is drastically reduced demonstrating the requirement of specific protein-DNA interaction for carrier protein-mediated gene transfer. To evaluate the specificity of TEG-mediated gene delivery further, the effect of specific competitors on luciferase expression were analyzed. COS-1 cells were treated with TEG-polyplex either in the absence or presence of a 30-fold molar excess of the EGF-receptor specific antibody 14E1 (24 nm final concentration), or a 10-fold molar excess of the natural ligand EGF (8 nm final concentration). The results are shown in Figure 5c . Both molecules efficiently competed with TEG for the binding to EGF receptor thereby drastically decreasing the expression of the luciferase reporter gene. These data confirm that TEG-mediated gene transfer is strictly dependent on the accessibility of EGF receptor on the surface of target cells.
Requirement of endosome escape activity for TEGmediated gene transfer
The efficiency of TEG-mediated gene transfer was also investigated using human A431 tumor cells which carry . As shown in Figures 2 and 3 , TEG binds to and activates EGF receptors on these cells. However, no efficient gene transfer could be obtained using a transfection protocol similar to that for COS-1 cells (Figure 6 ). In contrast, efficient luciferase reporter gene expression was observed after transfection of A431 cells in the presence of 100 m chloroquine.
Chloroquine has been shown to enhance the efficiency of various nonviral gene transfer vectors which utilize receptor-mediated endocytosis for DNA delivery. [21] [22] [23] It blocks endosomal acidification, but also accumulates in intracellular vesicles and induces osmotic swelling of the endosomes which could result in endosome destabilization and the release of internalized DNA. 24 Endosomal acidification is a process required for the activation of the exotoxin A translocation domain which serves as an endosome escape activity in carrier proteins such as TEG and the similar ErbB2-specific 5EG protein. 6 Therefore, the dependence of TEG-mediated gene transfer on endosomal acidification was investigated in COS-1 cells using different inhibitors of endosomal acidification. The cells were transfected with TEGpSV2G4LUC polyplex in the absence or presence of 100 m chloroquine, 50 mm methylamine, 10 m monensin, 5 m nigericin, or 200 nm Bafilomycin A1. The results are shown in Figure 7 . The addition of chloroquine as expected resulted in a 2.8-fold increase in reporter gene expression, whereas reagents which do not induce endosome disruption such as methylamine, monensin, nigericin, and Bafilomycin A1, similar to previous results with an ErbB2 specific carrier protein, 6, 25 led to a significant reduction in transfection efficiency. These data clearly show that in COS-1 cells endosomal acidification is required for full gene delivery activity of the TEG carrier protein and indicate that the exotoxin A translocation domain of TEG is functionally active. This suggests that cell type dependent factors such as different intracellular routing of TEG-EGF receptor complexes and rapid receptor recycling might be responsible for the observed dependence on chloroquine of TEG-mediated gene transfer in A431 cells.
cells per well and grown overnight. Then the cells were treated with TEG-pSV2G4LUC polyplex (TEG) at a final concentration of refolded TEG of 4 nm for 4 h as described in the legend to Figure 4 either in the presence or absence of 100 m chloroquine (Chl) as indicated. Control cells were incubated with pSV2G4LUC polyplex lacking the fusion protein (pL). Cells were harvested and reporter gene expression was analyzed 36 h later. Luciferase activity is expressed in relative light units per milligram of total protein.

Figure 7 TEG-mediated gene transfer is dependent on the activity of the translocation domain. COS-1 cells were treated with TEG-pSV2G4LUC polyplex at a final concentration of refolded TEG of 4 nm for 4 h in the
Discussion
Overexpression of the EGF receptor has been found in many human tumors of epithelial origin and has been correlated with unfavorable patient prognosis. 11 Since the EGF receptor is accessible on the cell surface and internalizes after ligand binding it is a suitable target for tumor-cell specific therapies which involve the intracellular delivery of macromolecules. This has been exploited for recombinant toxins with antitumoral activity which consist of natural EGF receptor ligands such as TGF-␣, or receptor-specific antibody domains fused to a bacterial toxin. 16, 19, 20 Similarly, several strategies have been developed to achieve the delivery of genetic material into EGF receptor-expressing cells. Direct targeting of retroviral vectors has been approached by engineering the Nterminus of the viral envelope protein via insertion of the natural ligand EGF. 13 Likewise EGF receptor-mediated delivery of nonviral vectors has been achieved using a chemical conjugate of polylysine and an EGF receptorspecific antibody 12 or a complex consisting of biotinylated EGF non-covalently bound to a streptavidin-polylysine conjugate. 14 In the latter case the addition of adenoviral particles linked to polylysine was required to facilitate efficient gene delivery into lung cancer cells.
We have chosen the EGF receptor as a target for a modular fusion protein, TEG, which combines in a single polypeptide chain DNA-binding, cell recognition, and endosome escape activities. The TEG protein is very similar in its structure to the previously described 5EG molecule 6 which facilitates cell-specific gene transfer and consists of a single chain antibody domain specific for the human ErbB2 receptor, an internal translocation domain derived from Pseudomonas exotoxin A, and the sequencespecific DNA-binding domain of the yeast GAL4 protein.
To investigate whether this concept could be adapted for distinct target cell populations, the N-terminal antibody domain of 5EG was replaced by the natural EGF receptor ligand TGF-␣ as a cell targeting domain. The resulting TEG protein retained endosome escape and DNA-binding activities but acquired a novel specificity for EGF receptor-expressing cells.
The TGF-␣ domain contains three disulfide bonds which upon expression in E. coli appear to be formed improperly resulting in decreased receptor binding activity. Therefore an additional denaturation/renaturation step was included in the purification protocol which greatly enhanced the activity of the TEG fusion protein. Incubation of EGF receptor expressing COS-1 cells with polyplex containing refolded TEG resulted in an up to 150-fold increase in reporter gene expression in comparison to polyplex alone. Thereby TEG-mediated gene transfer could be blocked by the addition of EGF or the antagonistic EGF receptor specific antibody 14E1 indicating that DNA uptake in these cells is mediated via specific binding of TEG-polyplex to the target receptor.
Complexes of the fusion protein and DNA must be internalized and reach an acidic environment before the ETA translocation domain can become activated and facilitate the escape of the DNA to the cytosol. Binding of growth factors to the EGF receptor triggers receptor dimerization followed by receptor activation and internalization of the ligand-receptor complex along the endocytic pathway, thereby initiation of signal transduction and internalization of the EGF receptor coincide. 17 TGF-␣ is depleted from the medium at a faster rate than EGF 26 and might therefore be a better candidate as a ligand for targeted gene delivery. Since the TEG fusion protein like natural growth factors induces autophosphorylation of the EGF receptor it is very likely that it also triggers rapid internalization. A further argument to select TGF-␣ came from the observation that TGF-␣ itself might provide some endosome escape activity. 19 Small chimeric toxins consisting only of the growth factor and ETA domain III in the absence of the translocation domain already exhibited high cytotoxic activity towards EGF receptorexpressing cells indicating that the toxin reached the cytosol. This additional activity of TGF-␣ might complement the function of the internal translocation domain in the TEG fusion protein.
The importance of an endosome escape activity for successful uptake and intracellular delivery of protein-DNA complexes via the EGF receptor has previously been demonstrated. Antibody-polylysine conjugates alone were not very efficient in DNA delivery. 12 Similarly, a complex of EGF and polylysine connected via a biotinstreptavidin linkage did not result in efficient transfection of cells unless adenoviral particles were provided as an endosomolytic activity.
14 Also retroviral vectors engineered to target EGF receptor-expressing cells required the addition of chloroquine for partial recovery of infectivity. 13 Here the TEG fusion protein mediated efficient gene delivery in COS-1 cells in the absence of additional endosome disturbing reagents and the transfection efficiency of TEG-polyplex could be strongly reduced by co-treatment of cells with different inhibitors of endosomal acidification. These results demonstrate that TEG, like the parental exotoxin A, is dependent on the transit through a low pH environment for full activity, and indicate that the bacterial translocation domain contributes to TEG-mediated gene delivery. In contrast, in EGF receptor overexpressing A431 cells TEG alone was unable to facilitate transfection, but for successful gene delivery was strictly dependent on the simultaneous presence of the endosome destabilizing reagent chloroquine. Similar results have also been obtained with EGF receptorexpressing HeLa human cervical carcinoma cells (data not shown).
The ETA translocation domain is effective in delivering the enzymatically active fragment of the wild-type toxin to the cytosol where a few active molecules are sufficient to cause cell death. 10 In the case of chimeric DNA carrier proteins which utilize this bacterial domain, much bigger complexes must be released from the endosomes and higher numbers of DNA molecules have to be delivered in order to achieve substantial gene expression. Therefore it is not surprising that the addition of supplementary endosome destabilizing reagents can further improve transfection efficiency. 6 Likewise the intracellular delivery of a heterologous protease domain by ETA sequences was enhanced in the presence of adenoviral particles. 27 However, the dependence on chloroquine of TEGmediated gene transfer in A431 cells was unexpected and suggests that cell type specific factors strongly affect the intracellular delivery of the TEG-containing polyplex.
Due to enhanced receptor recycling in A431 cells, 28 or altered intracellular routing, internalized TEG-EGFreceptor complexes might not reach an acidic environment or might not remain at low pH long enough to allow gene delivery to the cytosol. In addition, A431 cells respond abnormally to nanomolar concentrations of exogenous growth factors. Natural EGF receptor ligands usually stimulate cell proliferation while activation of EGF receptors in A431 cells can result in the suppression of cell growth, 29 most likely mediated via signaling through STAT proteins. 30 We have observed that TEG like TGF-␣ at concentrations which are nontoxic for COS-1 cells induced cell death in A431 cells (data not shown). While sublethal concentrations of TEG were used for the transfection experiments, it cannot be excluded that at least in this cell line continuing receptor activation by the TGF-␣ domain had an inhibitory effect on reporter gene uptake and expression. Previously the ErbB2-specific 5EG carrier protein which contains a recombinant antibody fragment 6 instead of a growth factor domain was shown to facilitate gene transfer in human tumor cells in the absence of chloroquine. Similarly, the use of a DNA-binding fusion protein harboring an EGF receptor-specific antibody domain 16, 20 instead of TGF-␣ might help to evaluate the influence of receptor activation on gene delivery further.
We have shown that the concept of modular fusion proteins for targeted gene delivery is versatile and allows the adaptation for different target cell populations by including a suitable cell recognition domain. The TGF-␣-containing TEG DNA carrier protein is able to specifically recognize and transfer genetic material into EGF receptor-expressing cells. Thereby cell type-specific factors appear to greatly influence transfection efficiencies and have to be considered for individual applications of this strategy. While the in vivo stability of protein-DNA complexes containing such modular fusion proteins remains to be established, their similarity to recombinant toxins which have already demonstrated their capability to reach established tumors in vivo 20, 31 suggests that they might become useful reagents for the targeted delivery of therapeutic genes in cancer gene therapy.
Materials and methods
Cell lines COS-1 SV40-transformed African green monkey kidney cells and A431 human epidermoid carcinoma cells were maintained in Dulbecco's modified Eagle's medium (DMEM; BioWhittaker, Verviers, Belgium) supplemented with 10% heat inactivated fetal bovine serum (FBS), 2 mm l-glutamine, 100 units/ml penicillin and 100 g/ml streptomycin at 37°C in a humidified atmosphere of air and 5% CO 2 .
Construction of the TEG fusion protein A DNA fragment encoding amino acids 1 to 50 of human TGF-␣, six consecutive histidine residues and amino acids 252 to 308 of exotoxin A (ETA) from Pseudomonas aeruginosa was derived by HindIII/SalI digestion of the plasmid pSW202-TGF␣ which encodes a TGF-␣-ETA fusion protein. 31 A second DNA fragment encoding amino acids 309 to 366 of ETA fused to amino acids 2 to 147 of the yeast transcriptional activator GAL4 was isolated from the plasmid pSW50-5EG 6 by SalI/XbaI digestion. The HindIII/SalI and the SalI/XbaI fragments were inserted into a HindIII/XbaI digested pFLAG-1 vector (Integra Biosciences, Fernwald, Germany). The resulting plasmid pWF47-TEG encodes under the control of the IPTG-inducible tac promoter the TEG fusion protein which consists of an E. coli ompA signal peptide, the synthetic FLAG epitope encoded by the vector, the human TGF-␣ domain, a cluster of six His residues, the ETA translocation domain, and the GAL4 DNA-binding domain.
Bacterial expression and purification of the TEG fusion protein E. coli CC118 carrying the plasmid pWF47-TEG were grown at 37°C to an OD 550 of 0.5 in LB medium containing 0.6% glucose and 100 g/ml ampicillin. Protein expression was induced for 1 h at 37°C by the addition of 0. Alternatively, for complete denaturation and reduction of disulfide bonds, eluates from the Ni 2+ -affinity column were directly treated with 0.3 m DTT for 2 h at room temperature. Then the samples were rapidly diluted to a protein concentration below 100 g/ml in refolding buffer containing 100 mm Tris-HCl, pH 8.0, 8 mm oxidized glutathione, 0.5 m l-arginine, 150 mm NaCl. Refolding of the protein was allowed to take place for 2 days at 10°C. Subsequently the renatured protein was concentrated and dialyzed as described above.
ELISA experiments
The binding of TEG to the EGF receptor was measured by ELISA as described. 16 Ninety-six-well microtiter plates coated with 100 ng/well of recombinant protein comprising the extracellular domain of the human EGF receptor were blocked with 3% BSA in TBS (10 mm Tris-HCl, pH 7.5, 150 mm NaCl). Fifty microliters of TEG at concentrations ranging from 0.05 to 333 nm were added to the wells and the plates were incubated for 1 h at room temperature. Unbound protein was removed, the wells were washed and incubated with MAb RK5C1 specific for the GAL4 DNA-binding domain (Santa Cruz Biotechnology, Heidelberg, Germany) for 1 h at room temperature followed by incubation with goat anti-mouse IgG coupled to alkaline phosphatase (Sigma, Deisenhofen, Germany). Specifically bound protein was detected by incubation with a solution of 100 mm glycine, 1 mm ZnCl 2 , 1 mm MgCl 2 , pH 10.4, 1 mg/ml p-nitrophenylphosphate disodium (Sigma) for 3 h at room temperature, then the absorbance at 405 nm was measured.
FACS analysis A431 cells (5 × 10 5 ) in PBS were incubated with 1.6 g of TEG in the presence or absence of 1 g of EGF (four-fold molar excess) for 40 min at 4°C. Unbound proteins were removed, cells were washed twice with PBS, and then treated with 3 g of the anti-FLAG MAb M2 (Integra Biosciences) for another 40 min followed by FITC-labeled goat anti-mouse IgG as a second antibody. Fluorescence of cells was analyzed with a fluorescence-activated cell sorter (FACScan; Becton Dickinson, Heidelberg, Germany).
EGF receptor activation assays COS-1 and A431 cells were grown for 8 h in DMEM containing 0.5% FCS. After removal of the medium, purified TEG was added at a concentration of 3 g/ml in PBS for 10 min at 37°C in the presence or absence of the antagonistic EGF-receptor specific monoclonal antibody 14E1 16 as a competitor. Control cells were treated with PBS or 100 ng/ml EGF. Cell lysis was performed in a buffer containing 50 mm Tris-HCl, pH 7.5, 5 mm EDTA, 150 mm NaCl, 1% Triton X-100, 2 mm NaVO 4 , 50 mm NaF and 10 mm Na-molybdate. Cleared cell lysates containing equal amounts of total proteins were separated by SDS-PAGE on a 7.5% gel and subsequently blotted on a PVDF membrane (Millipore, Eschborn, Germany). Phosphotyrosinecontaining proteins were detected with an antiphosphotyrosine monoclonal antibody (Santa Cruz Biotechnology), followed by incubation with an antimouse horseradish peroxidase coupled antibody and chemiluminescent detection with the ECL kit (Amersham, Braunschweig, Germany). The amount of EGF receptors in each lane was analyzed by reincubation of the membrane with the EGF-receptor specific 12E rabbit antiserum. 32 Transfection of cells with TEG-pSV2G4LUC polyplex Transfection complexes were prepared by incubation of 2 g pSV2G4LUC plasmid DNA 6 with variable amounts of the TEG fusion protein for 15 min at room temperature in a buffer containing 50 mm Hepes, pH 7.5, 0.1 mg/ml BSA, 50 mm KCl, 5 mm MgCl 2 , 100 m ZnCl 2 . To facilitate charge neutralization and condensation of the protein-DNA complex, 1.25 g of poly-l-lysine HBr (Sigma) with an average degree of polymerization of 236 residues (pL 236 ) were added slowly to the complex (pL 236 :DNA molar ratio of 50:1) and the mixture was incubated for an additional 15 min. For transfection, cells were seeded in 12-well tissue culture plates at a density of 4 × 10 4 cells per well and grown overnight at 37°C. Growth medium was exchanged with 1 ml per well of fresh medium 5 h before the addition of 100 l of protein-DNA complexes. The cells were incubated for 16 h at 37°C with TEG-polyplex at a final DNA concentration of 0.5 nm, a final pL 236 concentration of 25 nm, and the final TEG concentration as indicated in the respective Figure legends, then the medium was exchanged and the cells were grown for another 36 h before they were harvested for analysis.
Luciferase assay
The growth medium was removed, the cells were washed twice with PBS, and lysed for 15 min at room temperature in 100 l of buffer containing 25 mm glycylglycine, pH 7.8, 1 mm DTT, 15% glycerol, 8 mm MgSO 4 , 1 mm EDTA, and 1% Triton X-100. The lysates were cleared by centrifugation and protein content was determined. Fifty microliters of the lysate were mixed with an identical volume of dilution buffer containing 25 mm glycylglycine, pH 7.8, 10 mm MgSO 4 and 5 mm ATP. Luciferase activity was monitored for 30 s in a luminometer AutoLumat LB 953 (Berthold, Munich, Germany) with automatic injection of 300 l luciferin solution containing 250 mm luciferin (Sigma), 25 mm glycylglycine, pH 7.8 and 0.5 mm coenzyme A (Boehringer Mannheim, Mannheim, Germany). Luciferase activity was determined as relative light units per milligram of cellular protein.
